Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Conferences

ecancer travels so that you don't have to. Explore the latest conference coverage in global oncology and find out where we are going next.

ASH 2021

Axi-cel proves effective as first-line treatment for high-risk lymphoma

Axi-cel proves effective as first-line treatment for high-risk lymphoma

ASH 2021: Researchers present encouraging clinical trial results on novel therapy for bone marrow cancer

ASH 2021: Researchers present encouraging clinical trial results on novel therapy for bone marrow cancer

ASH 2021: Retrospective analysis of frontline treatment approach with treated secondary AML

ASH 2021: Retrospective analysis of frontline treatment approach with treated secondary AML

ASH 2021: Azacitidine with venetoclax and magrolimab shows high response rates in patients with newly diagnosed older/unfit or high-risk AML

ASH 2021: Azacitidine with venetoclax and magrolimab shows high response rates in patients with newly diagnosed...

$ASH 2021: Venetoclax in combination with gilteritinib demonstrates molecular clearance of FLT3 mutation in relapsed/refractory FLT3-mutated AML$

ASH 2021: Venetoclax in combination with gilteritinib demonstrates molecular clearance of FLT3 mutation in...

ASH 2021: New drug combo may improve family-donated stem cells as blood cancer treatment

ASH 2021: New drug combo may improve family-donated stem cells as blood cancer treatment

ASH 2021: Research identifies potential approach to mitigate CAR T-cell therapy toxicity

ASH 2021: Research identifies potential approach to mitigate CAR T-cell therapy toxicity

ASH 2021: Drug combination found to keep chronic lymphocytic leukaemia in young patients in remission for several years

ASH 2021: Drug combination found to keep chronic lymphocytic leukaemia in young patients in remission for several...

ASH 2021: Bispecific antibody shows 75% response rate at highest dose levels in heavily pretreated multiple myeloma

ASH 2021: Bispecific antibody shows 75% response rate at highest dose levels in heavily pretreated multiple myeloma

ASH 2021: Older adults at high risk for multiple myeloma precursor condition may benefit from screening

ASH 2021: Older adults at high risk for multiple myeloma precursor condition may benefit from screening

ASH 2021: Trial identifies five-drug combo for ‘ultra high risk’ bone marrow cancer

ASH 2021: Trial identifies five-drug combo for ‘ultra high risk’ bone marrow cancer

ASH 2021: Statistical models predict benefit of non-intensive AML therapy

ASH 2021: Statistical models predict benefit of non-intensive AML therapy

ASH 2021: Axicabtagene ciloleucel demonstrates potential as first-line therapy for patients with high-risk large B-cell lymphoma

ASH 2021: Axicabtagene ciloleucel demonstrates potential as first-line therapy for patients with high-risk large B...

ASH 2021: Axicabtagene ciloleucel shows durable responses after two years for patients with indolent non-Hodgkin lymphoma

ASH 2021: Axicabtagene ciloleucel shows durable responses after two years for patients with indolent non-Hodgkin...

ASH 2021: Bispecific antibody mosunetuzumab brings deep remission for follicular lymphoma

ASH 2021: Bispecific antibody mosunetuzumab brings deep remission for follicular lymphoma

ASH 2021: ZUMA-7 demonstrates lasting benefits of CAR-T therapy over current standard of care for large B-cell lymphoma

ASH 2021: ZUMA-7 demonstrates lasting benefits of CAR-T therapy over current standard of care for large B-cell...

ASH 2021: Immune-boosting antibody treatment isatuximab meets primary endpoint for multiple myeloma

ASH 2021: Immune-boosting antibody treatment isatuximab meets primary endpoint for multiple myeloma

$ASH 2021: TRANSFORM study reports CAR T-cell therapy liso-cel significantly improves outcomes for relapsed and refractory large B-cell lymphoma$

ASH 2021: TRANSFORM study reports CAR T-cell therapy liso-cel significantly improves outcomes for relapsed and...

ASH 2021: Study suggests need for earlier conversations about end-of-life decisions for patients with high-risk acute myeloid leukaemia

ASH 2021: Study suggests need for earlier conversations about end-of-life decisions for patients with high-risk...

ASH 2021: Ivosidenib combined with azacitidine improves outcomes for newly diagnosed acute myeloid leukaemia with IDH-1 mutation compared with azacitidine alone

ASH 2021: Ivosidenib combined with azacitidine improves outcomes for newly diagnosed acute myeloid leukaemia with...

ASH 2021: Persistent racial disparities in acute lymphoblastic leukaemia survival

ASH 2021: Persistent racial disparities in acute lymphoblastic leukaemia survival

More from ecancer